SecBot SecBot

CRVO drug pipeline

CervoMed Inc. · 1 rated drug
$1.67
−1.2% 1-day · Nov 16
Next catalyst
None dated
No dated FDA catalyst on file
Typical move on FDA news
No history
No past FDA events with prices
IV rank
No data
No current options data
Rated drugs
1
1 mixed
Phase 3 trials
0
0 with results posted

Drugs

soonest catalyst first
◆ mixed
Impact
PhasePhase 2b completed; Phase 3 planned but not yet initiated
Time to marketAt least 3-4 years, assuming a partnership is secured, Phase 3 initiates in H2 2026, completes enrollment and reads out (~2 years), then NDA submission and FDA review (~1 year).

neflamapimod Updated Jul 6

What to watch

Watch for a strategic partnership announcement to fund the Phase 3 DLB trial, this is the single biggest near-term catalyst and would validate the drug's commercial potential. However, be aware of heavy recent dilution (~$20.5M raised in June 2026), an S-3 resale shelf overhang, and the risk that Phase 3 may not begin without a partner. The stock trades near the low end of its 52-week range ($2.13-$13.13) with a ~$28M market cap; analyst mean target is $19.50 but these targets were set before the latest dilutive financings.

Bull case
  • Positive Phase 2b extension data with new capsule formulation showed statistically significant improvement on CDR-SB (p=0.035 vs placebo) and biomarker reduction (GFAP, p=0.003), suggesting the drug may work with proper dosing (source: ir.cervomed.com/news-releases).
  • FDA alignment on Phase 3 registration path in Nov 2025 validates the trial design, endpoints, and patient enrichment strategy, a major de-risking step for a small-cap biotech (source: ir.cervomed.com/news-releases).
  • Founder/Chairman Josh Boger invested $3M in the June 2026 PIPE at $3.14/share, signaling insider conviction.
Bear case
  • The initial Phase 2b topline (Dec 2024) failed its primary endpoint, causing the stock to drop ~79%. The positive extension data came from a subgroup analysis with a different capsule formulation, raising questions about reproducibility (source: biopharmcatalyst.com/news/2024).
  • Phase 3 is NOT yet funded, the company explicitly states initiation is contingent on a strategic partnership or additional financing (source: ir.cervomed.com/news-releases). With only ~$20.9M cash (FY2025) and cash runway into Q2 2027, the company may not have resources to execute a pivotal trial alone.
  • Heavy recent dilution: ~$20.5M raised in June 2026 via a PIPE (at $3.14) and a registered direct offering (at $4.00), plus an S-3 shelf registering 10M+ shares for resale, creating significant overhang.

Clinical trials

3 Phase 2/3
DrugTrialPhaseStatusEnrolledPrimary completion
neflamapimodA Clinical Study to Investigate the Effect of Oral Neflamapimod on Motor Recovery After Acute Ischaemic StrokePhase 2Completed45Sep 23, 2026
neflamapimodA Clinical Study of Neflamapimod in Patients With Dementia With Lewy BodiesPhase 2Completed26Mar 11, 2026
neflamapimodRewinD-LB - Clinical Study of Neflamapimod in Patients With Dementia With Lewy BodiesPhase 2Completed · results159May 29, 2025